Welcome to our dedicated page for Rani Therapeutics Holdings news (Ticker: RANI), a resource for investors and traders seeking the latest updates and insights on Rani Therapeutics Holdings stock.
Rani Therapeutics Holdings, Inc. (Nasdaq: RANI) is a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs through its proprietary RaniPill® capsule platform. The RANI news page on Stock Titan aggregates company press releases, market announcements and regulatory updates so readers can follow how this oral biologics platform is progressing through preclinical and clinical development.
According to the company’s disclosures, recent news has highlighted pipeline milestones, such as preclinical data and the initiation of a Phase 1 clinical trial for RT-114, an orally administered RaniPill capsule containing a GLP-1/GLP-2 dual agonist (PG-102) being developed for the treatment of obesity. Rani has also reported preclinical data on oral semaglutide (RT-116) and on oral delivery of a bispecific GLP-1/GLP-2 receptor agonist via RaniPill, with results described as comparable in bioavailability and weight loss to subcutaneous injections in animal models.
Investors and observers can use this news feed to track strategic collaborations and financings, including Rani’s Collaboration and License Agreement with Chugai Pharmaceutical Co., Ltd. for an oral product combining RaniPill HC with a rare disease antibody, and its collaboration with ProGen Co., Ltd. for RT-114 in weight management. The company’s announcements also cover private placements, registered offerings, warrant transactions and related board changes tied to institutional investors.
In addition, Rani’s news includes quarterly financial results and corporate updates, where management discusses cash runway expectations, research and development spending and progress across its oral biologics pipeline. For anyone following RANI stock or the evolution of oral delivery technologies for biologics, this page offers a centralized view of company-generated news, from clinical trial plans to collaboration agreements and capital markets activity.
SAN JOSE, Calif., May 3, 2022 (GLOBE NEWSWIRE) -- Rani Therapeutics, a clinical-stage biotherapeutics company, announced that CEO Talat Imran will present at two investment conferences in May. The Bank of America 2022 Healthcare Conference is scheduled for May 10 at 5:20 PM PT, while the H.C. Wainwright Annual Global Life Sciences Conference will take place on May 24 at 10:30 AM PT. Interested participants can access the live webcasts on Rani's Investor Relations page, with replays available for 90 days post-presentation.
Rani Therapeutics Holdings, Inc. (Nasdaq: RANI) has been recognized by Fast Company with the top honor in the Health category of the 2022 World Changing Ideas Awards for its RaniPill™ capsule. This innovative technology aims to replace painful injections for biologic drugs, facilitating oral delivery while maintaining high bioavailability. The capsule, which contains a dissolvable needle, is currently undergoing multiple clinical trials, with the company striving to be a leader in oral biologics across various therapeutic areas.
Rani Therapeutics Holdings (Nasdaq: RANI) announced that CEO Talat Imran will present at the 21st Annual Needham Virtual Healthcare Conference on April 14, 2022, at 12:45 p.m. PT / 3:45 p.m. ET. This event provides an opportunity for investors and interested parties to hear insights directly from Rani's leadership.
Participants can access the live audio webcast through Needham or the Investor Relations section of Rani's website. A replay will be available for 90 days after the event.
Rani Therapeutics has initiated a Phase 1 clinical trial of RT-102, an oral treatment for osteoporosis. The company launched the RaniPill™ High Capacity (HC), enhancing delivery capacity to over 20 mg. Financially, cash reserves rose to $117.5 million in 2021, supporting operations through 2023. R&D expenses surged to $26.5 million due to increased headcount and equity compensation. However, net losses also expanded to $53.1 million. The company anticipates topline Phase 1 data in 2H 2022 and plans further clinical trials.
Rani Therapeutics (Nasdaq: RANI) will announce its fourth quarter and full year 2021 financial results on March 29, 2022, after market close. A conference call to discuss these results will take place at 1:30 p.m. PT / 4:30 p.m. ET that same day. Rani Therapeutics focuses on the oral delivery of biologics, having developed the RaniPill™ capsule aimed at replacing subcutaneous injections. The company has conducted various preclinical and clinical studies to assess the safety and bioavailability of the RaniPill™ technology.
Rani Therapeutics (Nasdaq: RANI) announced the initiation of a Phase 1 study for RT-102, an oral formulation of the human parathyroid hormone analog PTH(1-34) aimed at treating osteoporosis. This study is critical as it utilizes the RaniPill™ capsule to deliver PTH orally, potentially improving patient adherence compared to daily self-injections. Conducted in Australia, the study will evaluate the pharmacokinetics, safety, and tolerability of RT-102 in healthy adult women. Rani aims to revolutionize the delivery of biologics with this innovative oral treatment.
Rani Therapeutics has announced the development of RaniPill™ HC, a high-capacity oral delivery device capable of delivering over 500% more biologic payload than its existing capsule. This device can potentially deliver up to 20mg of biologics, unlocking over 50 new drug opportunities. In preliminary financial results, the company estimates a net loss of $13-15 million for Q4 2021, up from $5.8 million in Q4 2020, and a full-year loss between $53-55 million, compared to $16.7 million in 2020. Cash reserves are approximately $117.5 million.
Rani Therapeutics has appointed Lisa Rometty to its Board of Directors, enhancing its leadership team. With over 25 years of experience in global commercialization and strategic partnerships within healthcare, Rometty aims to advance the RaniPill technology, which seeks to replace subcutaneous injections with oral biologics. CEO Talat Imran emphasized the significance of her expertise in product commercialization for the company’s future. Rani Therapeutics continues to focus on developing and commercializing its innovative RaniPill™ capsule technology, which has shown promise in preclinical and clinical studies.
Rani Therapeutics (Nasdaq: RANI) reported its Q3 2021 financial results, highlighting a net loss of $28.7 million compared to $2.9 million in Q3 2020. R&D expenses surged to $12.0 million, primarily due to increased headcount and equity-based compensation costs. General and administrative expenses soared to $15.8 million from $0.8 million in the prior year. Despite the losses, Rani possesses $129.7 million in cash, expected to sustain operations through at least the end of 2023. The completion of a GLP study for RT-102 and preparations for a Phase I study in 2022 are notable advancements.
Rani Therapeutics Holdings (Nasdaq: RANI) announced the appointment of Lyn Baranowski to its Board of Directors, effective November 12, 2021. Baranowski brings 18 years of experience in the biotechnology sector, having held key roles at Altavant Sciences, Melinta Therapeutics, and AstraZeneca. CEO Talat Imran emphasized her expertise in strategic partnerships and financial transactions, which will be pivotal as Rani progresses its oral biologics delivery technology, RaniPill. This innovation aims to transform patient care by replacing injections with oral alternatives.